Search results for "Invasive"

showing 10 items of 1141 documents

Robotic versus laparoscopic surgery in gynecology: Which should we use?

2015

This review of the literature aims at assessing the safety and effectiveness of robotic versus laparoscopic surgery in benign and malignant gynecological diseases. Robotic-assisted laparoscopy is already widely used in the United States and Europe for the main gynecological procedure - hysterectomy - and has proved feasible and comfortable for other benign and malignant gynecological procedures. However, the clinical effectiveness and safety of robotic surgery compared with standard laparoscopy have not been undoubtedly established. We reviewed the literature by searching in the Ovid/MEDLINE, PubMed, Cochrane Library, and Google Scholar databases for all the articles published from January …

Obstetrics and GynecologyRobotic surgical procedureHysterectomyGynecologic Surgical ProceduresSettore MED/40 - GINECOLOGIA E OSTETRICIAMinimally invasive surgical proceduresHumansFemaleHysterectomy; Laparoscopy; Minimally invasive surgical procedures; Robotic surgical procedures; Obstetrics and GynecologyLaparoscopyRobotic surgical proceduresGenital Diseases FemaleMinimally invasive surgical procedure
researchProduct

Caliper navigation for craniotomy planning of convexity targets.

2021

Introduction A technique to localize a radiological target on the head convexity fast and with acceptable precision is sufficient for surgeries of superficial intracranial lesions, and of help in the setting of emergency surgery, computer navigation breakdown, limited resources and education. We present a caliper technique based on fundamental geometry, with inexpensive and globally available tools (conventional CT or MRI image viewer, calculator, caliper). Methods The distances of the radiological target from two landmarks (nasion and porus acusticus externus) are assessed with an image viewer and Pythagoras’ theorem. The two distances are then marked around the landmarks onto the head of…

Offset (computer science)Computer sciencemedicine.medical_treatmentDistance MeasurementConvexityDiagnostic RadiologyNervous System ProceduresMedicine and Health SciencesComputer navigationMusculoskeletal SystemCraniotomyMeasurementMultidisciplinaryRadiology and ImagingQRBrainMagnetic Resonance ImagingNavigationmedicine.anatomical_structureSurgery Computer-AssistedMedicineEngineering and TechnologyNasionAnatomyCraniotomyResearch ArticleImaging TechniquesScienceSurgical and Invasive Medical ProceduresResearch and Analysis MethodsImaging Three-DimensionalSigns and SymptomsDiagnostic MedicinemedicineHumansRC346-429NeuronavigationSkeletonScalpbusiness.industrySkullBiology and Life SciencesLesionsIntracranial lesionsCalipersNeurology. Diseases of the nervous systemClinical MedicineNuclear medicinebusinessTomography X-Ray ComputedLimited resourcesHeadPloS one
researchProduct

Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.

2013

Contribution over time of human papillomavirus (HPV) types in human cancers has been poorly documented. Such data is fundamental to measure current HPV vaccines impact in the years to come. We estimated the HPV type-specific distribution in a large international series of invasive cervical cancer (ICC) over 70 years prior to vaccination. Paraffin embedded ICC cases diagnosed between 1940 and 2007 were retrieved from eleven countries in Central-South America, Asia and Europe. Included countries reported to have low-medium cervical cancer screening uptake. Information on age at and year of diagnosis was collected from medical records. After histological confirmation, HPV DNA detection was per…

OncologyAdultCancer ResearchInvasive cervical cancermedicine.medical_specialtyAsiavirusesUterine Cervical NeoplasmsHPV vaccinesLogistic regressionInternal medicinemedicineHumansNeoplasm InvasivenessHuman papillomavirusEarly Detection of CancerAgedRetrospective StudiesGynecologyCervical cancerHuman papillomavirus 16Paraffin EmbeddingHuman papillomavirus 18business.industryTime trendsMedical recordvirus diseasesCentral AmericaMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationEuropeLogistic ModelsOncologyDNA ViralFemalebusinessInternational journal of cancer
researchProduct

Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advan…

2020

Aim To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences. Methods Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized RO…

OncologyAdultMalemedicine.medical_specialtyT2 mappingWorld Health OrganizationWorld health030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMagnetic resonance imaging T2 mappingGliomaInternal medicinemedicineMutational statusHumansRadiology Nuclear Medicine and imagingNeoplastic DiseasesAgedRetrospective StudiesAged 80 and overbusiness.industryBrain NeoplasmsNon invasiveGeneral MedicineGliomaMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingIsocitrate DehydrogenaseMRI - Magnetic resonance imagingIsocitrate dehydrogenaseMutationFemaleNeurology (clinical)Neoplasm Gradingbusiness030217 neurology & neurosurgery
researchProduct

Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes--correlation with clinico-pathological parameters and…

2001

OBJECTIVE To assess whether the presence of human papilloma virus (HPV) DNA and/or several genotypes of HPV DNA in primary cervical cancer and cancer free pelvic lymph nodes are correlated with several clinicopathological parameters of well-defined prognostic significance and whether virological parameters are predictors of long-term survival in cancer patients. PATIENTS AND METHODS 223 cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the high sensitive polymerase chain reaction (PCR) method followed by …

OncologyAdultmedicine.medical_specialtyGenotypeUterine Cervical NeoplasmsAdenocarcinomaPolymerase Chain Reactionlaw.inventionCarcinoma AdenosquamouslawInternal medicineGenotypeMedicineHumansNeoplasm InvasivenessLymph nodePapillomaviridaePolymerase chain reactionAgedRetrospective StudiesCervical cancerAged 80 and overbusiness.industryPapillomavirus InfectionsObstetrics and GynecologyCancerMiddle Agedmedicine.diseasePrognosisPrimary tumorSurvival AnalysisKoilocyteTumor Virus Infectionsmedicine.anatomical_structureLymphatic MetastasisDNA ViralCarcinoma Squamous CellFemaleLymphLymph NodesbusinessFollow-Up StudiesZentralblatt fur Gynakologie
researchProduct

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

2011

Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …

OncologyAdultmedicine.medical_specialtyInvasive cervical cancerGenotypeUterine Cervical NeoplasmsHPV vaccinesAdenocarcinomaAlphapapillomavirusInternal medicineGenotypemedicineHumansPapillomavirus VaccinesHuman papillomavirusGenotypingAgedGynecologyCervical cancerHuman papillomavirus 16HPV typesVaccinesHpv typesHuman papillomavirus 18business.industryHPV PositivePapillomavirus Infectionsvirus diseasesObstetrics and GynecologyTime trendsMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOncologySpainCervical cancerFemalebusiness
researchProduct

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study.

2015

Abstract Introduction The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). Methods We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2−, HER-2+, and Triple Negative) as variables for univariat…

OncologyAdultmedicine.medical_specialtyLymphovascular invasionReceptor ErbB-2Sentinel lymph nodeClinical Decision-Makingbreast cancer axillary surgery sentinel lymph node biopsy adjuvant treatment biological prognostic factors.Breast NeoplasmsTriple Negative Breast NeoplasmsCohort StudiesBreast cancerInternal medicineMedicineHumansNeoplasm InvasivenessSettore SECS-S/05 - Statistica SocialeLymph nodeAgedNeoplasm StagingRetrospective StudiesGynecologyAged 80 and overbusiness.industrySentinel Lymph Node BiopsyAge FactorsCancerRetrospective cohort studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseSettore MED/18 - Chirurgia GeneraleExact testmedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemalebusinessInternational journal of surgery (London, England)
researchProduct

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer.

2017

The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case. In total, 90 features were obtained, including 88 imaging features related to morphology and texture as well as dynamic features from tumor and …

OncologyCancer Treatmentlcsh:MedicineInvasive Ductal CarcinomaLogistic regression030218 nuclear medicine & medical imagingDiagnostic Radiology0302 clinical medicineMathematical and Statistical TechniquesBreast TumorsImage Processing Computer-AssistedMedicine and Health Scienceslcsh:ScienceMultidisciplinarymedicine.diagnostic_testHuman epidermal growth factorRadiology and ImagingMiddle AgedMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisArea Under CurvePhysical SciencesFemaleAlgorithmsStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyImaging TechniquesImage processingBreast NeoplasmsResearch and Analysis MethodsCarcinomasSkewness03 medical and health sciencesBreast cancerText miningDiagnostic MedicineInternal medicineImage Interpretation Computer-AssistedBreast CancermedicineBiomarkers TumorHumansStatistical MethodsDifferentiated TumorsAgedNeoplasm StagingReceiver operating characteristicbusiness.industrylcsh:RCancers and NeoplasmsMagnetic resonance imagingLuminal amedicine.diseaseImage EnhancementProbability TheoryProbability Distributionlcsh:QNeoplasm GradingbusinessMathematicsForecastingPloS one
researchProduct

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

2018

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysi…

OncologyHepatocellular carcinomalaw.inventionLeukocyte Count0302 clinical medicineRandomized controlled trialNeutrophil-tolymphocyte ratiolawMedicineNeutrophil-to-lymphocyte ratioLiver NeoplasmsGastroenterologyMicroRNAGeneral MedicineSorafenibPrognosisTreatment OutcomeLiver030220 oncology & carcinogenesisHepatocellular carcinomaBiomarker (medicine)030211 gastroenterology & hepatologyAdverse events; Angiopoietin; Biomarker; Hepatocellular carcinoma; MicroRNA; Neutrophil-tolymphocyte ratio; Polymorphisms; Sorafenib; Vascular endothelial growth factor; Gastroenterologymedicine.drugAdverse eventSorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsSingle-nucleotide polymorphismAngiopoietin03 medical and health sciencesInternal medicineBiomarkers TumorHumansNeoplasm InvasivenessPolymorphismNeutrophil to lymphocyte ratioAdverse effectbusiness.industryBiomarkermedicine.diseasedigestive system diseasesClinical Trials Phase III as TopicDrug Resistance NeoplasmAdverse eventsEtiologyVascular endothelial growth factorbusinessPolymorphisms
researchProduct